ArticleJournal of cachexia, sarcopenia and muscle2025
Risks of All-Cause Mortality in Adults With Chronic Kidney Disease With Sarcopenia or Obesity: A Population-Based Study.
Article in Journal of cachexia, sarcopenia and muscle, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Anemia and hemoglobin thresholds of 12.5 and 13.0 g/dL are associated with distinct cardiovascular and all-cause mortality risks in COPD.International journal of cardiology. Cardiovascular risk and prevention · 2026Article
- Association between glomerular filtration rate and comprehensive geriatric assessment parameters in older adults.International urology and nephrology · 2026Article
- Photon-counting CT for paraspinal muscle fat quantification compared with MRI proton density fat fraction.BMC medical imaging · 2026Article
- Association between sarcopenia and mortality in patients with osteoarthritis.Clinical rheumatology · 2026Article
- Sarcopenic obesity and body composition phenotypes in older adults with chronic kidney disease: associations with estimated mortality risk.Scientific reports · 2026Article
- Association between the C-reactive protein-triglyceride-glucose index and asthma risk: evidence from the NHANES cohort and validation in the CHNS cohort.Clinics (Sao Paulo, Brazil) · 2026Article
- Unravelling Sarcopenia in Chronic Kidney Disease: From Pathogenesis to Diagnosis and Therapeutics.Diagnostics (Basel, Switzerland) · 2026Review
- Association of magnesium depletion score, triglyceride-glucose index, and C-reactive protein-albumin-lymphocyte index with diabetic sarcopenia: a cross-sectional study based on NHANES 2014-2018 data.American journal of translational research · 2026Article
- Stress Pathways in Chronic Kidney Disease: Linking Cortisol, Oxidative Stress, and Inflammation.Antioxidants (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe relationship between obesity, sarcopenic obesity and all-cause mortality in chronic kidney disease (CKD) patients remains controversial. This study aims to investigate the role of low muscle mass and fat mass in the risk of all-cause mortality in CKD patients in the United States.
methodsThis study utilized data from the National Health and Nutrition Examination Survey (NHANES) conducted between 1999-2006 and 2011-2018, including 1553 adults with CKD. Multivariable Cox proportional hazards models were constructed to explore the relationship between sarcopenia, fat mass and all-cause mortality, with nonlinear relationships assessed using restricted cubic splines. Subgroup analyses were conducted based on sex, CKD stages and the presence of sarcopenia.
resultsThe average age of participants was 58.15 ± 18.48 years, with 45% being male. Sarcopenia was more common in men, non-diabetic individuals and those with lower education levels. During a median follow-up of 119.5 months, 693 deaths from all causes were recorded. After adjusting for multiple variables, sarcopenia was significantly associated with increased all-cause mortality risk in CKD patients (HR 1.21; 95% CI 1.00-1.45, p = 0.047). Participants were categorized based on body mass index (BMI) into normal (reference), sarcopenia only, obesity only and sarcopenic obesity groups. Results showed that obesity alone had a protective effect in CKD Stages I-II (HR 0.45, 95% CI 0.28-0.72, p = 0.001) whereas it had an opposite effect in CKD Stages III-V (CKD III: HR 1.67, 95% CI 1.07-2.60, p = 0.024; CKD IV-V: HR 17.51, 95% CI 1.29-238.01, p = 0.032). Further analysis of fat mass data revealed that compared with the lowest quartile (Q1), middle and higher quartiles of fat mass showed significant benefits in male participants (Q2: HR 0.71, 95% CI 0.51-0.99, p = 0.046; Q3: HR 0.62, 95% CI 0.41-0.92, p = 0.019) and those in CKD Stage III (Q2: HR 0.64, 95% CI 0.47-0.88, p = 0.006; Q3: HR 0.62, 95% CI 0.41-0.93, p = 0.021).
conclusionsIn this longitudinal cohort study, we found that sarcopenia was associated with an increased risk of all-cause mortality in CKD patients, whereas moderate or higher fat mass might mitigate this risk, particularly in male patients. Prognostic management for CKD patients should focus on increasing muscle mass rather than simply reducing body weight.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.